Andrew A. Taylor
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: University of Toronto (1997); NOAA National Weather Service (2014); Wave Life Sciences (United States) (2021); University of Oklahoma (2005)
Faculty Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Andrew A. Taylor's research has focused on the evaluation of novel therapeutic agents. His work includes the pre-clinical assessment of NEOS-223, a peptidomimetic compound derived from (S)-valine-thiazole, for its potential as an anticancer agent and its activity as a P-glycoprotein inhibitor. Taylor has also published on topics related to speech acts and conversation, as well as historical and cultural analyses of Viking society and tattoos.
With an h-index of 3, Taylor has contributed to 13 publications, which have garnered 106 citations. His recent scholarly activity includes publications in 2022, indicating ongoing engagement in research.
Metrics
- h-index: 3
- Publications: 13
- Citations: 106
Selected Publications
-
Tattoos, “Tattoos,” Vikings, “Vikings,” and Vikings (2022)
Collaboration Network
Top Collaborators
- Abstract P39: Pre-clinical evaluation of NEOS-223, an (S)-valine-thiazole derived peptidomimetic N-heterocycle, as an anticancer agent and P-glycoprotein inhibitor
- Abstract P39: Pre-clinical evaluation of NEOS-223, an (S)-valine-thiazole derived peptidomimetic N-heterocycle, as an anticancer agent and P-glycoprotein inhibitor
- Abstract P39: Pre-clinical evaluation of NEOS-223, an (S)-valine-thiazole derived peptidomimetic N-heterocycle, as an anticancer agent and P-glycoprotein inhibitor
- Abstract P39: Pre-clinical evaluation of NEOS-223, an (S)-valine-thiazole derived peptidomimetic N-heterocycle, as an anticancer agent and P-glycoprotein inhibitor
- Abstract P39: Pre-clinical evaluation of NEOS-223, an (S)-valine-thiazole derived peptidomimetic N-heterocycle, as an anticancer agent and P-glycoprotein inhibitor
Similar Researchers
Based on overlapping research topics